Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Fax Cover Sheet

Date: 07 Aug 2003

To: Mary Tung	From: David J Steadman
Application/Control Number: 09/403,269	Art Unit 1652
Fax No.: 202-371-2600_ 202-371-2540	Phone No.: 703-308-3934
Voice No.: 202-371-2600	Return Fax No.: 703-308-4242
Re: suggestions for daim amendment	CC:
Urgent For Review For Comment	For Reply Per Your Request
Comments:	
See attached text.	
David	

Number of pages $\underline{2}$ including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

09/403,269

1708.0380000/MAC/MBT

Suggested alterations to claims:

- In claim 64, change "claims" to "claim" in line 2 to correct grammar.
- In claims 67, 68, and 72, remove "or said isolated complementary polynucleotide that hybridizes to same". This limitation has lack of antecedent basis, lacks written description (there is no functional limitation associated with the polynucleotide), and there is no definition of the hybridization conditions.
- In claims 73-75, remove "or an isolated complementary polynucleotide that hybridizes to same". This limitation lacks written description (there is no functional limitation associated with the polynucleotide) and there is no definition of the hybridization conditions.
- In claim 79, it is unclear what "said polynucleotide sequence" refers to in claim 65. Does it refer to "An isolated polynucleotide", "a nucleic acid sequence which encodes a polypeptide" or "a target polynucleotide"?
- In claim 80, remove recitation of deletion of internal regions. This limitation lacks written description as the nucleic acid reads on allelic variants that have not been described.